Chronic Lower Back Pain Market Expected to rise, 2034 | Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, BioDelivery Sciences International, Camurus, Braeburn Inc., Scilex Holding

The Chronic Lower Back Pain market growth is driven by factors like increase in the prevalence of Chronic Lower Back Pain, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Chronic Lower Back Pain market report [https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Chronic Lower Back Pain market size, share, Chronic Lower Back Pain epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Lower Back Pain market size growth forward.

Some of the key highlights from the Chronic Lower Back Pain Market Insights Report:

*
Several key pharmaceutical companies, including Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, BioDelivery Sciences International, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc., Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal and Biologics, Frontier Biotechnologies, DiscGenics Inc., Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, SpineThera, and others, are developing novel products to improve the Chronic Lower Back Pain treatment outlook.

*
In January 2025, Pacira BioSciences, Inc. secured FDA clearance for its Smart Tip, designed to target medial branch nerves for chronic low back pain management. The iovera system provides a drug-free approach, utilizing cryoneurolysis to deliver cold therapy, temporarily disrupting pain signals.

*
Chronic Lower Back Pain (CLBP) lasts 12+ weeks, even after the initial cause resolves. It's a common issue affecting millions.

*
In 2023, the U.S. led the 7MM CLBP market at ~$4.2B, projected to grow at a 4% CAGR. Opioids like Xtampza ER & BELBUCA dominated treatment, making up ~$2.96B of the market.

*
Despite ~68M diagnosed cases, no CLBP-specific approved therapies exist. The market is driven by aging, sedentary lifestyles & new treatments.

*
Scilex's SP-102 (SEMDEXA), a non-opioid injection for sciatica, may reshape the CLBP landscape upon its expected 2025 U.S. launch.

*
As per DelveInsight analysis, the Chronic Lower Back Pain market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Chronic Lower Back Pain Market Landscape [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Lower Back Pain Overview

Chronic low back pain (CLBP) lasts 12+ weeks, even after the initial injury or cause has healed. It's a widespread condition that most people experience at some point. The exact cause remains unclear, but when back pain persists for over three months, it's classified as CLBP. As the second leading cause of disability worldwide, CLBP poses a major economic and social challenge. Its prevalence has surged in recent years, especially among aging populations. Beyond physical discomfort, CLBP has psychological impacts and contributes to lost productivity, high treatment costs, and disability-related expenses. #Healthcare #CLBP

Do you know the treatment paradigms for different countries? Download our Chronic Lower Back Pain Market Sample Report [https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Lower Back Pain Epidemiology Insights

*
In 2023, the U.S. had approximately 31 million diagnosed cases of CLBP, making up about 45% of the 7MM population. The EU4 and the UK together accounted for 40%, while Japan contributed 15%. Among the EU4, Spain had the highest CLBP prevalence (8.6M cases), followed by Germany (6.3M), while France reported the lowest (5M).

Chronic Lower Back Pain Epidemiology Segmentation

DelveInsight's Chronic Lower Back Pain market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Lower Back Pain historical patient pools and forecasted Chronic Lower Back Pain patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Lower Back Pain Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

*
Chronic Lower Back Pain Prevalence

*
Age-Specific Chronic Lower Back Pain Prevalence

*
Gender-Specific Chronic Lower Back Pain Prevalence

*
Diagnosed and Treatable Cases of Chronic Lower Back Pain

Visit for more @ Chronic Lower Back Pain Epidemiological Insights [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Lower Back Pain Market Outlook

Chronic low back pain (CLBP) is a complex condition, much like how each patient experiences a unique disease progression. Consequently, treatment plans are highly individualized. Various classes of medications, each with a distinct mechanism of action, allow healthcare providers to target specific aspects of a patient's pain. Additionally, patient-specific factors are carefully considered when designing a treatment regimen to enhance adherence and improve outcomes.

The majority (80-90%) of low back pain cases originate from mechanical causes, such as degenerative disc or joint disease, vertebral fractures, or structural deformities. Less commonly, neurogenic, inflammatory, and other etiologies contribute to the condition. Initial pharmacologic treatment should be based on the underlying cause; however, as pain becomes chronic, a broader, multimodal approach is often required due to the diminishing effectiveness of targeted therapies.

For inflammatory-related low back pain, treatment typically involves anti-inflammatory medications. This includes the early use of nonsteroidal anti-inflammatory drugs (NSAIDs) and, in cases of conditions like rheumatoid arthritis or ankylosing spondylitis, corticosteroids or disease-modifying antirheumatic drugs (DMARDs).

To effectively manage severe pain and improve patient quality of life, certain medications have received FDA approval for long-term, around-the-clock opioid treatment when alternative therapies are insufficient. These include Xtampza (Collegium Pharmaceutical) and BELBUCA (buprenorphine HCL buccal film; BioDelivery Sciences International).

Chronic Lower Back Pain Marketed Drugs

*
XTAMPZA ER (oxycodone): Collegium Pharmaceutical

Chronic Lower Back Pain Emerging Drugs

*
Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited/Grunenthal

*
Semdexa (SP-102): Scilex Holding Company

Chronic Lower Back Pain Key Companies

*
Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, BioDelivery Sciences International, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc., Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal and Biologics, Frontier Biotechnologies, DiscGenics Inc., Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, SpineThera, and others

For more information, visit Chronic Lower Back Pain Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Chronic Lower Back Pain Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Chronic Lower Back Pain, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Chronic Lower Back Pain epidemiology in the 7MM

*
Chronic Lower Back Pain marketed and emerging therapies

*
Chronic Lower Back Pain companies

*
Chronic Lower Back Pain market drivers and barriers

Table of Contents:

1 Chronic Lower Back Pain Market Key Comprehensive Insights

2 Chronic Lower Back Pain Market Report Introduction

3 Competitive Intelligence Analysis for Chronic Lower Back Pain

4 Chronic Lower Back Pain Market Analysis Overview at a Glance

5 Executive Summary of Chronic Lower Back Pain

6 Chronic Lower Back Pain Epidemiology and Market Methodology

7 Chronic Lower Back Pain Epidemiology and Patient Population

8 Chronic Lower Back Pain Patient Journey

9 Chronic Lower Back Pain Treatment Algorithm, Chronic Lower Back Pain Current Treatment, and Medical Practices

10 Key Endpoints in Chronic Lower Back Pain Clinical Trials

11 Chronic Lower Back Pain Marketed Therapies

12 Chronic Lower Back Pain Emerging Therapies

13 Chronic Lower Back Pain: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Chronic Lower Back Pain

16 Chronic Lower Back Pain Market Key Opinion Leaders Reviews

18 Chronic Lower Back Pain Market Drivers

19 Chronic Lower Back Pain Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Chronic Lower Back Pain Epidemiology 2034

DelveInsight's "Chronic Lower Back Pain - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Lower Back Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Lower Back Pain Pipeline 2024

"Chronic Lower Back Pain Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Lower Back Pain market. A detailed picture of the Chronic Lower Back Pain pipeline landscape is provided, which includes the disease overview and Chronic Lower Back Pain treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-lower-back-pain-market-expected-to-rise-2034-eli-lilly-and-company-collegium-pharmaceutical-purdue-pharma-lp-biodelivery-sciences-international-camurus-braeburn-inc-scilex-holding]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.